Sign In
Buy RVPH
$0.695
+0.0350 (+5.30%)
At Close: Jun 23, 2026
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
04:08pm, Tuesday, 07'th Oct 2025
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
09:26pm, Thursday, 18'th Sep 2025
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
04:05pm, Thursday, 18'th Sep 2025
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
04:25pm, Thursday, 14'th Aug 2025
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial–
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
08:40am, Thursday, 26'th Jun 2025
CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
04:17pm, Wednesday, 25'th Jun 2025
CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
08:00am, Thursday, 05'th Jun 2025
CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation �
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
04:05pm, Thursday, 15'th May 2025
– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment –
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
11:30am, Sunday, 30'th Mar 2025
CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Tuesday, 04'th Feb 2025
CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva to Participate in the 2025 BIO CEO & Investor Conference
08:00am, Thursday, 30'th Jan 2025
CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
08:00am, Tuesday, 07'th Jan 2025
CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Announces Proposed Public Offering
05:18pm, Monday, 16'th Dec 2024
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low
03:37pm, Wednesday, 11'th Dec 2024
Reviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine, showing promising Phase 3 data but needing funding for a second trial to meet FDA requirements. Reviva should announc
